Product Details
VYVGART 400MG/20ML SDV DS
Manufacturer: ARGENX US INC SUBQ/DS
MFG#: 73475-3041-05
NDC: 73475-3041-05
PID: 639390
1/EA
$8,322.48
In StockAdditional Information
| Product Name | Vyvgart 400 mg/20mL SDV Ds |
| Active Ingredient | Efgartigimod alfa-fcab |
| Mechanism of Action | Binds to neonatal Fc receptor (FcRn), reducing circulating IgG autoantibody levels |
| Strength | 400 mg per 20 mL vial (20 mg/mL) |
| Route of Administration | Intravenous (IV) |
| Common Side Effects | Headache, respiratory tract infections, urinary tract infections, infusion-related reactions |
| Serious Risks | Increased risk of infections, hypersensitivity reactions, possible immunosuppression |
| Dilution Requirements | Must be diluted with 0.9% sodium chloride before administration |
| Precautions | Monitor for infections, hypersensitivity reactions, and changes in IgG levels |
| Packaging | Single-use vial |
| Storage Conditions | Refrigerate at 2°C to 8°C (36°F to 46°F); protect from light; do not freeze or shake |
| Usage | Treatment of anti-AChR antibody-positive generalized myasthenia gravis |
Description
Vyvgart 20 mg/mL (400 mg) is a single-dose, preservative-free intravenous infusion containing efgartigimod alfa-fcab, a human IgG1-derived Fc fragment. It is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody-positive. Efgartigimod alfa-fcab functions by binding to the neonatal Fc receptor (FcRn), reducing IgG autoantibody levels and improving neuromuscular function in affected patients.
The recommended dosing regimen consists of a treatment cycle of four weekly intravenous infusions, with subsequent cycles based on clinical evaluation. The drug must be administered over an infusion period under medical supervision. Common adverse effects include headache, respiratory tract infections, urinary tract infections, and infusion-related reactions.
Clinical assessments should include IgG levels and signs of hypersensitivity reactions. Live vaccines should be avoided during treatment due to potential immunosuppression. Caution is advised in patients with pre-existing infections or risk factors for severe infections. The drug's effects on pregnancy and lactation remain under investigation, necessitating careful risk-benefit assessment.
Frequently Asked Questions (FAQs)
The cost of VYVGART 400MG/20ML SDV DS is $$8,322.48
VYVGART 400MG/20ML SDV DS is manufactured by ARGENX US INC SUBQ/DS.
You can purchase VYVGART 400MG/20ML SDV DS on our website at https://supplies.pipelinemedical.com/product/detail/vyvgart-400mg-20ml-sdv-ds-639051